Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OPKO HealthLTS:0KCS +0.83%57 Debt-to-EBITDA is -3.57 as of Mar. 2026. GuruFocus rates LTS:0KCS with a GF Score™ of 57/100 and a GF Value™ of $1.06 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 112 Medical Diagnostics & Research companies, OPKO Health ranks worse than 892856.25% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for OPKO Health's Debt-to-EBITDA or its related term are showing as below:
LTS:0KCS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -11.45 Med: -1.05 Max: 14.68
Current: -11.45
During the past 13 years, the highest Debt-to-EBITDA Ratio of OPKO Health was 14.68. The lowest was -11.45. And the median was -1.05.
LTS:0KCS's Debt-to-EBITDA is ranked worse than 100% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.29
vs LTS:0KCS: -11.45
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
OPKO Health Debt-to-EBITDA Related Terms
OPKO Health Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for OPKO Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0KCS vs PSNL, CDNA, CSTL: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, OPKO Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OPKO Health Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where OPKO Health's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
OPKO Health (LTS:0KCS) has a Debt-to-EBITDA of -3.57 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on OPKO Health. According to the industry distribution chart, OPKO Health ranks #999999 out of 112 companies in the Medical Diagnostics & Research industry.
Is OPKO Health's Debt-to-EBITDA too high?
OPKO Health's current Debt-to-EBITDA is -3.57. Based on the distribution chart, OPKO Health ranks #999999 out of 112 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, OPKO Health has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OPKO Health's Debt-to-EBITDA compare to PSNL and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, OPKO Health ranks #999999 out of 112 companies for Debt-to-EBITDA. This places OPKO Health in the lower half of its industry. The industry median Debt-to-EBITDA is 2.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.29, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on OPKO Health. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OPKO Health's current Debt-to-EBITDA is -3.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OPKO Health stock overvalued right now?
Based on GuruFocus' analysis, OPKO Health (LTS:0KCS) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.06, compared to a current price of $1.21 — trading 14.2% above its estimated fair value. The current Debt-to-EBITDA is -3.57. OPKO Health's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For OPKO Health (LTS:0KCS), the current Debt-to-EBITDA is -3.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OPKO Health (LTS:0KCS) Overvalued in 2026?
Based on GuruFocus' analysis, OPKO Health stock appears to be overvalued.
The current stock price of $1.21 is trading 14.2% above its estimated GF Value™ of $1.06.
GuruFocus considers OPKO Health to be Modestly Overvalued.
Key valuation signals for LTS:0KCS:
Debt-to-EBITDA: -3.57
GF Value™: $1.06 vs. price of $1.21 (14.2% above fair value)
No single metric tells the full story. See the LTS:0KCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
57GF Score
Get the complete analysis for LTS:0KCS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0KCS has been successfully added to your 
